These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23047118)

  • 1. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
    Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
    Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
    Mo H; Hedskog C; Lawitz E; Brainard DM; Yang J; Delaney W; Worth A; Miller MD
    Antiviral Res; 2017 Apr; 140():151-157. PubMed ID: 28132867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
    J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.
    Dvory-Sobol H; Wong KA; Ku KS; Bae A; Lawitz EJ; Pang PS; Harris J; Miller MD; Mo H
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5289-95. PubMed ID: 22869562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
    Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
    J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
    Lawitz EJ; Gruener D; Hill JM; Marbury T; Moorehead L; Mathias A; Cheng G; Link JO; Wong KA; Mo H; McHutchison JG; Brainard DM
    J Hepatol; 2012 Jul; 57(1):24-31. PubMed ID: 22314425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
    Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
    Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
    Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
    J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
    McPhee F; Friborg J; Levine S; Chen C; Falk P; Yu F; Hernandez D; Lee MS; Chaniewski S; Sheaffer AK; Pasquinelli C
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3670-81. PubMed ID: 22508297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
    Svarovskaia ES; Martin R; McHutchison JG; Miller MD; Mo H
    J Clin Microbiol; 2012 Oct; 50(10):3267-74. PubMed ID: 22837328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
    Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT
    J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
    de Bruijne J; Thomas XV; Rebers SP; Weegink CJ; Treitel MA; Hughes E; Bergmann JF; de Knegt RJ; Janssen HL; Reesink HW; Molenkamp R; Schinkel J
    J Viral Hepat; 2013 Nov; 20(11):779-89. PubMed ID: 24168257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.
    Moreno C; Berg T; Tanwandee T; Thongsawat S; Van Vlierberghe H; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G
    J Hepatol; 2012 Jun; 56(6):1247-53. PubMed ID: 22326470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.